These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18182994)

  • 1. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
    Mitra A; Fisher C; Foster CS; Jameson C; Barbachanno Y; Bartlett J; Bancroft E; Doherty R; Kote-Jarai Z; Peock S; Easton D; ; Eeles R
    Br J Cancer; 2008 Jan; 98(2):502-7. PubMed ID: 18182994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
    Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA
    Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
    Bancroft EK; Page EC; Brook MN; Pope J; Thomas S; Myhill K; Helfand BT; Talaty P; Ong KR; Douglas E; Cook J; Rosario DJ; Salinas M; Buys SS; Anson J; Davidson R; Longmuir M; Side L; Eccles DM; Tischkowitz M; Taylor A; Cruellas M; Ballestero EP; Cleaver R; Varughese M; Barwell J; LeButt M; Greenhalgh L; Hart R; Azzabi A; Jobson I; Cogley L; Evans DG; Rothwell J; Taylor N; Hogben M; Saya S; ; Eeles RA; Aaronson NK
    BJU Int; 2024 Sep; 134(3):484-500. PubMed ID: 38839570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
    Bancroft EK; Page EC; Castro E; Lilja H; Vickers A; Sjoberg D; Assel M; Foster CS; Mitchell G; Drew K; Mæhle L; Axcrona K; Evans DG; Bulman B; Eccles D; McBride D; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Selkirk C; Hulick PJ; Bojesen A; Skytte AB; Lam J; Taylor L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Blanco I; Salinas M; Cook J; Rosario DJ; Buys S; Conner T; Ausems MG; Ong KR; Hoffman J; Domchek S; Powers J; Teixeira MR; Maia S; Foulkes WD; Taherian N; Ruijs M; Helderman-van den Enden AT; Izatt L; Davidson R; Adank MA; Walker L; Schmutzler R; Tucker K; Kirk J; Hodgson S; Harris M; Douglas F; Lindeman GJ; Zgajnar J; Tischkowitz M; Clowes VE; Susman R; Ramón y Cajal T; Patcher N; Gadea N; Spigelman A; van Os T; Liljegren A; Side L; Brewer C; Brady AF; Donaldson A; Stefansdottir V; Friedman E; Chen-Shtoyerman R; Amor DJ; Copakova L; Barwell J; Giri VN; Murthy V; Nicolai N; Teo SH; Greenhalgh L; Strom S; Henderson A; McGrath J; Gallagher D; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Costello P; Eyfjord J; Rothwell J; Falconer A; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Kote-Jarai Z; Lubinski J; Axcrona U; Melia J; McKinley J; Mitra AV; Moynihan C; Rennert G; Suri M; Wilson P; Killick E; ; Moss S; Eeles RA
    Eur Urol; 2014 Sep; 66(3):489-99. PubMed ID: 24484606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
    Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
    Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
    Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
    Mitra AV; Jameson C; Barbachano Y; Sodha N; Kote-Jarai Z; Javed A; Bancroft E; Fletcher A; Cooper C; Peock S; ; Easton D; Eeles R; Foster CS
    Oncol Rep; 2010 Feb; 23(2):299-305. PubMed ID: 20043088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
    Maier C; Herkommer K; Luedeke M; Rinckleb A; Schrader M; Vogel W
    Prostate; 2014 Oct; 74(14):1444-51. PubMed ID: 25111659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
    Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
    Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
    Mitra AV; Bancroft EK; Barbachano Y; Page EC; Foster CS; Jameson C; Mitchell G; Lindeman GJ; Stapleton A; Suthers G; Evans DG; Cruger D; Blanco I; Mercer C; Kirk J; Maehle L; Hodgson S; Walker L; Izatt L; Douglas F; Tucker K; Dorkins H; Clowes V; Male A; Donaldson A; Brewer C; Doherty R; Bulman B; Osther PJ; Salinas M; Eccles D; Axcrona K; Jobson I; Newcombe B; Cybulski C; Rubinstein WS; Buys S; Townshend S; Friedman E; Domchek S; Ramon Y Cajal T; Spigelman A; Teo SH; Nicolai N; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Eyfjord J; Falconer A; Grönberg H; Hamdy F; Johannsson O; Khoo V; Kote-Jarai Z; Lilja H; Lubinski J; Melia J; Moynihan C; Peock S; Rennert G; Schröder F; Sibley P; Suri M; Wilson P; Bignon YJ; Strom S; Tischkowitz M; Liljegren A; Ilencikova D; Abele A; Kyriacou K; van Asperen C; Kiemeney L; ; Easton DF; Eeles RA
    BJU Int; 2011 Jan; 107(1):28-39. PubMed ID: 20840664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Genomic Domains in
    Patel VL; Busch EL; Friebel TM; Cronin A; Leslie G; McGuffog L; Adlard J; Agata S; Agnarsson BA; Ahmed M; Aittomäki K; Alducci E; Andrulis IL; Arason A; Arnold N; Artioli G; Arver B; Auber B; Azzollini J; Balmaña J; Barkardottir RB; Barnes DR; Barroso A; Barrowdale D; Belotti M; Benitez J; Bertelsen B; Blok MJ; Bodrogi I; Bonadona V; Bonanni B; Bondavalli D; Boonen SE; Borde J; Borg A; Bradbury AR; Brady A; Brewer C; Brunet J; Buecher B; Buys SS; Cabezas-Camarero S; Caldés T; Caliebe A; Caligo MA; Calvello M; Campbell IG; Carnevali I; Carrasco E; Chan TL; Chu ATW; Chung WK; Claes KBM; Collaborators GS; Collaborators E; Cook J; Cortesi L; Couch FJ; Daly MB; Damante G; Darder E; Davidson R; de la Hoya M; Puppa LD; Dennis J; Díez O; Ding YC; Ditsch N; Domchek SM; Donaldson A; Dworniczak B; Easton DF; Eccles DM; Eeles RA; Ehrencrona H; Ejlertsen B; Engel C; Evans DG; Faivre L; Faust U; Feliubadaló L; Foretova L; Fostira F; Fountzilas G; Frost D; García-Barberán V; Garre P; Gauthier-Villars M; Géczi L; Gehrig A; Gerdes AM; Gesta P; Giannini G; Glendon G; Godwin AK; Goldgar DE; Greene MH; Gutierrez-Barrera AM; Hahnen E; Hamann U; Hauke J; Herold N; Hogervorst FBL; Honisch E; Hopper JL; Hulick PJ; Investigators K; Investigators H; Izatt L; Jager A; James P; Janavicius R; Jensen UB; Jensen TD; Johannsson OT; John EM; Joseph V; Kang E; Kast K; Kiiski JI; Kim SW; Kim Z; Ko KP; Konstantopoulou I; Kramer G; Krogh L; Kruse TA; Kwong A; Larsen M; Lasset C; Lautrup C; Lazaro C; Lee J; Lee JW; Lee MH; Lemke J; Lesueur F; Liljegren A; Lindblom A; Llovet P; Lopez-Fernández A; Lopez-Perolio I; Lorca V; Loud JT; Ma ESK; Mai PL; Manoukian S; Mari V; Martin L; Matricardi L; Mebirouk N; Medici V; Meijers-Heijboer HEJ; Meindl A; Mensenkamp AR; Miller C; Gomes DM; Montagna M; Mooij TM; Moserle L; Mouret-Fourme E; Mulligan AM; Nathanson KL; Navratilova M; Nevanlinna H; Niederacher D; Nielsen FCC; Nikitina-Zake L; Offit K; Olah E; Olopade OI; Ong KR; Osorio A; Ott CE; Palli D; Park SK; Parsons MT; Pedersen IS; Peissel B; Peixoto A; Pérez-Segura P; Peterlongo P; Petersen AH; Porteous ME; Pujana MA; Radice P; Ramser J; Rantala J; Rashid MU; Rhiem K; Rizzolo P; Robson ME; Rookus MA; Rossing CM; Ruddy KJ; Santos C; Saule C; Scarpitta R; Schmutzler RK; Schuster H; Senter L; Seynaeve CM; Shah PD; Sharma P; Shin VY; Silvestri V; Simard J; Singer CF; Skytte AB; Snape K; Solano AR; Soucy P; Southey MC; Spurdle AB; Steele L; Steinemann D; Stoppa-Lyonnet D; Stradella A; Sunde L; Sutter C; Tan YY; Teixeira MR; Teo SH; Thomassen M; Tibiletti MG; Tischkowitz M; Tognazzo S; Toland AE; Tommasi S; Torres D; Toss A; Trainer AH; Tung N; van Asperen CJ; van der Baan FH; van der Kolk LE; van der Luijt RB; van Hest LP; Varesco L; Varon-Mateeva R; Viel A; Vierstraete J; Villa R; von Wachenfeldt A; Wagner P; Wang-Gohrke S; Wappenschmidt B; Weitzel JN; Wieme G; Yadav S; Yannoukakos D; Yoon SY; Zanzottera C; Zorn KK; D'Amico AV; Freedman ML; Pomerantz MM; Chenevix-Trench G; Antoniou AC; Neuhausen SL; Ottini L; Nielsen HR; Rebbeck TR
    Cancer Res; 2020 Feb; 80(3):624-638. PubMed ID: 31723001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
    Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA;
    Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
    Edwards SM; Evans DG; Hope Q; Norman AR; Barbachano Y; Bullock S; Kote-Jarai Z; Meitz J; Falconer A; Osin P; Fisher C; Guy M; Jhavar SG; Hall AL; O'Brien LT; Gehr-Swain BN; Wilkinson RA; Forrest MS; Dearnaley DP; Ardern-Jones AT; Page EC; Easton DF; Eeles RA;
    Br J Cancer; 2010 Sep; 103(6):918-24. PubMed ID: 20736950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.
    Horsburgh S; Matthew A; Bristow R; Trachtenberg J
    Prostate; 2005 Oct; 65(2):124-9. PubMed ID: 15880530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2.
    Roed Nielsen H; Petersen J; Therkildsen C; Skytte AB; Nilbert M
    Acta Oncol; 2016; 55(1):38-44. PubMed ID: 26360800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival.
    Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
    Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    Ibrahim M; Yadav S; Ogunleye F; Zakalik D
    BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
    Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
    Bancroft EK; Saya S; Page EC; Myhill K; Thomas S; Pope J; Chamberlain A; Hart R; Glover W; Cook J; Rosario DJ; Helfand BT; Hutten Selkirk C; Davidson R; Longmuir M; Eccles DM; Gadea N; Brewer C; Barwell J; Salinas M; Greenhalgh L; Tischkowitz M; Henderson A; Evans DG; Buys SS; ; ; Eeles RA; Aaronson NK
    BJU Int; 2019 Feb; 123(2):284-292. PubMed ID: 29802810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.